This page contains details about ViiV Healthcare clinical trials. Approved prescribing information must continue to guide appropriate use of ViiV Healthcare medicines. This information may vary from country to country. Before prescribing any product mentioned in this section, Healthcare Professionals should consult prescribing information approved in their country.
Use the filters below to find out more about ViiV Healthcare clinical trials for dolutegravir/lamivudine, cabotegravir▼ & rilpivirine▼, fostemsavir▼ and dolutegravir/rilpivirine▼.
Showing results for
NP-GBL-HVX-WCNT-220013 April 2022